Immune checkpoint inhibitor-associated encephalitis in a small-cell lung cancer patient
10.12025/j.issn.1008-6358.2026.20260029
- VernacularTitle:小细胞肺癌患者免疫检查点抑制剂相关脑炎1例报告
- Author:
Miao LI
1
;
Qunying HONG
1
;
Yuanlin SONG
2
;
Sulan WEI
1
;
Nuo XU
1
Author Information
1. Department of Respiratory and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
2. Department of Respiratory and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China;Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai 200032, China;Shanghai Institute of Infectious Disease and Biosecurity, Shanghai 200032, China;Shanghai Respiratory Research Institute, Shanghai 200032, China.
- Publication Type:Clinicalcaseanalysis
- Keywords:
small-cell lung cancer;
immune checkpoint inhibitor;
immune-related adverse event;
encephalitis
- From:
Chinese Journal of Clinical Medicine
2026;33(4):729-735
- CountryChina
- Language:Chinese
-
Abstract:
The neurotoxicity related to immune checkpoint inhibitors (ICI) is rare, and the clinical experience remains limited. This paper reported an elderly male patient with advanced small cell lung cancer (SCLC). Following two circles of chemotherapy combined with immunotherapy (serplulimab, 200 mg), the patient developed fatigue, cognitive impairment, motor apraxia, and ataxia. Based on the examination of blood neurotransmitters and brain magnetic resonance imaging, the patient was diagnosed with ICI-associated encephalitis, and his symptoms improved after hormone treatment.
